The sale of Agilex Biolabs, the bioanalytical laboratories arm of Australian healthcare services provider Healius, has attracted significant interest from international private equity firms, with a competitive field emerging as the process unfolds. Among the suitors is EQT, the Swedish buyout firm managing over €200 billion ($328 billion) in assets globally, which is reportedly examining the opportunity alongside at least four other interested parties, including Blackstone.

EQT’s interest in Agilex aligns with its broader strategic focus on the clinical trials and life sciences services sector. Over the past five years, EQT has built a substantial presence in this area, notably through its 2021 acquisition of Parexel, a leading US-based contract research organization (CRO), which was purchased with Goldman Sachs for $5.8 billion. Parexel operates across 49 countries, providing pharmacokinetics and clinical pharmacology services that typically depend on specialist bioanalytical laboratories such as Agilex.

Further underscoring EQT’s commitment to the life sciences ecosystem, the firm acquired Swedish biotech Mabtech earlier this year. Mabtech develops immunoassay kits and tools for immune response research, which complements Agilex’s core capabilities in immunogenicity and biomarker analysis. In Australia, EQT also owns Icon Group, the country's largest integrated cancer care provider and operator of the most extensive private cancer clinical trials program, reinforcing its footprint within clinical trial operations.

Agilex, which has operated for 25 years as Australia’s largest and longest-standing bioanalytical CRO, would extend EQT’s geographic reach and enhance its service offerings within clinical trials and life sciences. The company provides critical regulated bioanalytical services to biotechnology and pharmaceutical clients, making it a strategic fit.

The sale process has also attracted parties attentive to the clinical trials sector more broadly. Some interested investors have reportedly evaluated Nucleus Network, a clinical trials business owned by Blackstone and poised for sale, indicating growing private equity activity in Australia’s clinical research landscape.

Healius aims to secure between $150 million and $200 million for Agilex, a significant discount from the $301 million it paid in 2021. The initial acquisition was valued at approximately 20 times forecast earnings before interest, tax, depreciation, and amortization (EBITDA), at a time when pathology assets commanded premium prices amid the COVID-19 pandemic. However, Agilex has since underperformed relative to those elevated expectations. Factors such as the normalization of global supply chains, the return of imported produce to Australian supermarkets, and a stronger Australian dollar have all contributed to pressures on farmgate returns, affecting the business’s valuation in this sale process.